A5048456616- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Prostate Cancer Treatment and Research
- Radiation Therapy and Dosimetry
- HER2/EGFR in Cancer Research
- Radioactive Decay and Measurement Techniques
- Medical Imaging and Pathology Studies
- Radioactive element chemistry and processing
- Peptidase Inhibition and Analysis
- Advanced Radiotherapy Techniques
- X-ray Diffraction in Crystallography
- Crystallization and Solubility Studies
- Nuclear Physics and Applications
- Glioma Diagnosis and Treatment
- Particle accelerators and beam dynamics
- Radioactivity and Radon Measurements
- Immunotherapy and Immune Responses
- Lymphoma Diagnosis and Treatment
- Lanthanide and Transition Metal Complexes
- Lung Cancer Treatments and Mutations
- RNA Interference and Gene Delivery
- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- Nuclear physics research studies
Joint Research Centre
2016-2025
University of Pretoria
2023-2024
Steve Biko Hospital
2023
Karlsruhe University of Education
2020-2021
European Commission
2010-2020
Technion – Israel Institute of Technology
2012
Memorial Sloan Kettering Cancer Center
2010
UNSW Sydney
2006
Directorate-General Joint Research Centre
2004
Lintuzumab (HuM195), a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest single-agent activity against acute (AML). To increase the potency of antibody without nonspecific cytotoxicity associated with β-emitters, α-particle-emitting radionuclide bismuth-213 ((213)Bi) was conjugated to lintuzumab. This phase I/II trial conducted determine maximum tolerated dose (MTD) antileukemic effects (213)Bi-lintuzumab, first targeted α-emitter, after partially cytoreductive chemotherapy.
This work describes a method for the separation and purification of Ac-225 from Th-229 source. The procedure is based on combination ion exchange extraction chromatographic methods in nitric acid media allows preparation carrier-free, clinical grade with an overall yield exceeding 95%. Quality control product performed using radiometric (α, γ spectrometry) mass spectrometric methods. can be loaded radionuclide generator Bi-213 preclinical studies targeted α therapy cancer infectious diseases.
225Ac-PSMA-617 has demonstrated good anti-tumor effect as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients. No study previously assessed outcome and survival following of de novo hormone-sensitive carcinoma (mHSPC) Based on the potential side effects that are known explained to patients by oncologist, some refused standard seeking alternative therapies. Thus, we report our preliminary findings in retrospective series 21 mHSPC options were treated with...
Background The lifespan of red blood cells is terminated when macrophages remove senescent by erythrophagocytosis. This puts at the center systemic iron recycling in addition to their functions tissue remodeling and innate immunity. Thus far, erythrophagocytosis has been studied evaluating phagocytosis erythrocytes that were damaged mimic senescence. These studies have demonstrated acquisition some specific individual senescence markers can trigger macrophages, but we hypothesized mechanism...
Targeted α-therapy is an experimental approach to the management of cancer. Short range α-particle radiation from a radioisotope attached targeting monoclonal antibody kills targeted cancer cells. Survival results are analyzed previously reported Phase I study systemic for patients with stage IV metastatic melanoma or in-transit metastases. Following intravenous administration 46–925 MBq α-immunoconjugate, 213Bi-cDTPA-9.2.27, 38 were followed observe response and toxicity. Responses measured...
Hypoxia is a central problem in tumor treatment because hypoxic cells are less sensitive to chemo- and radiotherapy than normoxic cells. Radioresistance of due reduced sensitivity towards low Linear Energy Transfer (LET) radiation. High LET α-emitters thought eradicate independent cellular oxygenation. Therefore, the aim this study was demonstrate that cell-bound α-particle emitting 213Bi immunoconjugates kill CAL33 with identical efficiency. For purpose were incubated 213Bi-anti-EGFR-MAb or...
Endoradiotherapy approaches are experiencing growing interest with the increase in number of carrier molecules becoming available for different targets. The cross-fire effect has been described as an important mechanism efficacy radioligand therapies by particle-induced destruction
Abstract Increasing attention is given to personalized tumour therapy, where α-emitters can potentially play an important role. Alpha particles are ideal for localized cell killing because of their high linear energy transfer and short ranges. However, upon the emission α particle daughter nuclide experiences a recoil large enough ensure decoupling from any chemical bond. These ‘free’ nuclides no longer targeted accumulate in normal tissue. In this paper, we used polymersomes as model...
AbstractPurpose. The aim is to assess toxicity and response of systemic alpha therapy for metastatic melanoma.Experimental design. This an open-labelled Phase 1 dose escalation study establish the effective alpha-immunoconjugate 213Bi-cDTPA-9.2.27 mAb (AIC). Tools used investigate effects were physical examination; imaging tumours; pathology; GFR; CT changes in tumour marker. Responses assessed using RECIST criteria. Results Discussion. 22 patients with stage IV melanoma/ in-transit...
Peptide receptor radionuclide therapy (PRRT) is an established treatment for nonoperable or metastatic neuroendocrine neoplasms that highly and frequently express somatostatin receptors. More generally, PRRT attractive option delivering cytotoxic radiation to tumor cells through specific binding of a radiolabeled peptide molecular target. The development imaging companions gave rise the concept radiotheranostics, important in vivo detection, characterization, staging but also, more...
Targeted alpha-particle therapy (TAT) might be a relevant therapeutic strategy to circumvent resistance conventional therapies in the case of HER2-positive metastatic cancer. Single-domain antibody fragments (sdAb) are promising vehicles for TAT because their excellent vivo properties, high target affinity, and fast clearance kinetics. This study combines cytotoxic α-particle emitter bismuth-213 (213Bi) HER2-targeting sdAbs. The vitro specificity, potency radiolabeled complex were analyzed...
// Katharina Teiluf 1,* , Christof Seidl 1,2,* Birgit Blechert 1 Florian C. Gaertner 1,3 Klaus-Peter Gilbertz 4 Vanesa Fernandez 5 Bassermann Jan Endell 6 Rainer Boxhammer Stephane Leclair Mario Vallon 1,7 Michaela Aichler 8 Annette Feuchtinger Frank Bruchertseifer 9 Alfred Morgenstern and Markus Essler Department of Nuclear Medicine, Technische Universität München, Munich, Germany 2 Obstetrics Gynecology, 3 Universitätsklinikum Bonn, Institute Radiobiology, German Armed Forces, III. Medical...
Background Absorbed doses for α-emitters are different from those β-emitters, as the high linear energy transfer (LET) nature of α-particles results in a very dense deposition over relatively short path length near point emission. This highly localized and therefore can lead to enhanced cell-killing effects at absorbed that non-lethal low-LET type exposure. Affinities DOTA-DPhe1-Tyr3-octreotate (DOTATATE), 115In-DOTATATE, 175Lu-DOTATATE 209Bi-DOTATATE were determined K562-SST2 cell line. Two...
Barium ferrite nanoparticles (BaFeNPs) were investigated as vehicles for
Overexpression of human epidermal growth factor receptor type 2 (HER2) occurs in multiple carcinomas. For example, up to 20% breast cancer cases are classified as HER2 positive (HER2+). Treatment this condition typically involves immunotherapy using monoclonal antibodies, such trastuzumab or pertuzumab. The precise targeting antibodies HER2+ tumour lesions can be used well radioimmunotherapy deliver medical radionuclides exactly the afflicted area and therefore minimize radiation exposure...